279 related articles for article (PubMed ID: 16585598)
21. HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers.
Vulcano F; Ciccarelli C; Mattia G; Marampon F; Giampiero M; Milazzo L; Pascuccio M; Zani BM; Giampaolo A; Hassan HJ
Exp Cell Res; 2006 May; 312(9):1590-7. PubMed ID: 16739251
[TBL] [Abstract][Full Text] [Related]
22. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen.
Li N; Zhao D; Kirschbaum M; Zhang C; Lin CL; Todorov I; Kandeel F; Forman S; Zeng D
Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4796-801. PubMed ID: 18347343
[TBL] [Abstract][Full Text] [Related]
23. Hepatoprotection and lethality rescue by histone deacetylase inhibitor valproic acid in fatal hemorrhagic shock.
Gonzales ER; Chen H; Munuve RM; Mehrani T; Nadel A; Koustova E
J Trauma; 2008 Sep; 65(3):554-65. PubMed ID: 18784568
[TBL] [Abstract][Full Text] [Related]
24. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Qi H; Ratnam M
Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
[TBL] [Abstract][Full Text] [Related]
25. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
26. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
[TBL] [Abstract][Full Text] [Related]
27. HDAC inhibitors restore C-fibre sensitivity in experimental neuropathic pain model.
Matsushita Y; Araki K; Omotuyi Oi; Mukae T; Ueda H
Br J Pharmacol; 2013 Nov; 170(5):991-8. PubMed ID: 24032674
[TBL] [Abstract][Full Text] [Related]
28. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
Leng C; Gries M; Ziegler J; Lokshin A; Mascagni P; Lentzsch S; Mapara MY
Exp Hematol; 2006 Jun; 34(6):776-87. PubMed ID: 16728283
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Richon VM; Sandhoff TW; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
[TBL] [Abstract][Full Text] [Related]
30. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
31. Pentyl-4-yn-VPA, a histone deacetylase inhibitor, ameliorates deficits in social behavior and cognition in a rodent model of autism spectrum disorders.
Foley AG; Cassidy AW; Regan CM
Eur J Pharmacol; 2014 Mar; 727():80-6. PubMed ID: 24486700
[TBL] [Abstract][Full Text] [Related]
32. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
33. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
34. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
Sanchez-Gonzalez B; Yang H; Bueso-Ramos C; Hoshino K; Quintas-Cardama A; Richon VM; Garcia-Manero G
Blood; 2006 Aug; 108(4):1174-82. PubMed ID: 16675713
[TBL] [Abstract][Full Text] [Related]
35. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
[TBL] [Abstract][Full Text] [Related]
36. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40.
Long J; Zhao J; Yan Z; Liu Z; Wang N
Int J Cancer; 2009 Mar; 124(5):1235-44. PubMed ID: 19058176
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors promote osteoblast maturation.
Schroeder TM; Westendorf JJ
J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3.
Wetzel A; Scholtka B; Gerecke C; Kleuser B
Cell Mol Life Sci; 2020 Dec; 77(23):5017-5030. PubMed ID: 31955243
[TBL] [Abstract][Full Text] [Related]
40. HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury.
Ruess DA; Probst M; Marjanovic G; Wittel UA; Hopt UT; Keck T; Bausch D
PLoS One; 2016; 11(8):e0161233. PubMed ID: 27513861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
